Product nameAnti-KMT2A / MLL antibody [BL-175-7E8]
See all KMT2A / MLL primary antibodies
DescriptionRabbit monoclonal [BL-175-7E8] to KMT2A / MLL
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Synthetic peptide within Human KMT2A/ MLL aa 720-780 (N terminal). The exact sequence is proprietary. Gene ID 4297. Found in the N-terminal 300 kDa fragment generated by proteolytic cleavage and in isoform 14P-18B of MLL1.
Database link: Q03164
This product is sold under License from Bethyl Laboratories, Inc.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 8.2
Preservative: 0.09% Sodium azide
Constituent: 99% Borate buffered saline
Concentration information loading...
Purification notesRecombinant antibody was purified from cell culture supernatant.
Our Abpromise guarantee covers the use of ab243867 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.
Use 10µl/0.5mg lysate.
FunctionHistone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis.
Tissue specificityHeart, lung, brain and T- and B-lymphocytes.
Involvement in diseaseNote=Chromosomal aberrations involving MLL are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with MLLT4/AF6; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins MLL-MLLT1, MLL-MLLT3 and MLL-ELL interact with PPP1R15A and, on the contrary to unfused MLL, inhibit PPP1R15A-induced apoptosis.
Note=A chromosomal aberration involving MLL may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11.
Sequence similaritiesBelongs to the histone-lysine methyltransferase family. TRX/MLL subfamily.
Contains 3 A.T hook DNA-binding domains.
Contains 1 bromo domain.
Contains 1 CXXC-type zinc finger.
Contains 1 FY-rich C-terminal domain.
Contains 1 FY-rich N-terminal domain.
Contains 3 PHD-type zinc fingers.
Contains 1 post-SET domain.
Contains 1 SET domain.
Domainthe 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
The SET domain structure is atypical and is not in an optimal position to have methyltransferase activity. It requires other components of the MLL1/MLL complex, such as ASH2L or RBBP5, to order the active site and obtain optimal histone methyltransferase activity.
The CXXC-type zinc finger binds bind to nonmethyl-CpG dinucleotides.
modificationsProteolytic cleavage by TASP1 generates MLL cleavage product N320 and MLL cleavage product C180, which reassemble through a non-covalent association. 2 cleavage sites exist, cleavage site 1 (CS1) and cleavage site 2 (CS2), to generate MLL cleavage products N320 and C180. CS2 is the major site.
Cellular localizationNucleus and Nucleus. Localizes to a diffuse nuclear pattern when not associated with MLL cleavage product N320.
- Information by UniProt
- ALL-1 antibody
- ALL1 antibody
- C-terminal cleavage product of 180 kDa antibody
KMT2A / MLL was immunoprecipitated from 1 mg HEK-293T whole cell lysate with ab243867 at 10 µl per reaction Western blot was performed on the immunoprecipitate using ab243867 at 1/1000 dilution.
Lane 1: ab243867 IP in HEK-293T cell lysate.
Lane 2: Contol IgG in HEK-293T cell lysate.
Detection: Chemiluminescence with an exposure time of 3 minutes.
Western blot analysis using ab243867 at 1/1000 dilution.
Lane 1: HEK-293T whole cell lysate (50 µg).
Lane 2: HeLa whole cell lysate (50 µg).
Lane3: MCF7 whole cell lysate (50 µg).
Lane 4: HepG2 whole cell lysate (50 µg).
Lane 5: A549 whole cell lysate (50 µg).
Lane 6: SW620 whole cell lysate (50 µg).
a HRP-conjugated goat anti-rabbit IgG antibody was used as the secondary. Detection: chemiluminescence with an exposure time of 3 minutes.
ab243867 has not yet been referenced specifically in any publications.